目的 观察灯盏生脉胶囊联合左西孟旦注射液治疗慢性心力衰竭的临床疗效。方法 选取2019年1月—2021年3月在新乡市第一人民医院接受治疗的102例慢性心力衰竭患者，将患者根据随机数字表法分为对照组和治疗组，每组各51例。对照组给予左西孟旦注射液，起始静脉注射负荷量为12 μg/kg，之后静脉滴注0.15～0.20μg/(kg∙min)，1次/周。治疗组在对照组治疗的基础上口服灯盏生脉胶囊，2粒/次，3次/d。两组均连续治疗4周。观察两组的临床疗效，比较两组的心功能指标、血清因子水平。结果 治疗后，治疗组总有效率为92.16%，高于对照组的总有效率70.59%（P＜0.05）。治疗后，两组左心室舒张末期内径（LVEDD）、左心室收缩末期容积（LVESV）、左心室收缩末期内径（LVESD）均显著降低，左室射血分数（LVEF）、心指数（CI）显著升高（P＜0.05），且治疗组LVEDD、LVESV、LVESD低于对照组，LVEF、CI高于对照组（P＜0.05）。治疗后，两组血清C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、N末端B型钠尿肽原（NT-proBNP）、肌钙蛋白T（cTnT）水平较治疗前显著降低（P＜0.05），且治疗组血清CRP、TNF-α、IL-6、NT-proBNP、cTnT水平明显低于对照组（P＜0.05）。结论 灯盏生脉胶囊联合左西孟旦注射液治疗慢性心力衰竭疗效显著，可促进心功能恢复，降低血清因子水平，且具有较好的安全性。

Objective To observe the therapeutic effect of Dengzhan Shengmai Capsules combined with Levosimendan Injection in treatment of chronic heart failure. Methods Patients (84 cases) with chronic heart failure in Xinxiang First People's Hospital from January 2019 to March 2021 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were iv administered with Levosimendan Injection, the initial intravenous load was 12 μg/kg, and followed by intravenous drip of 0.15-0.20 μg/(kg∙min), once weekly. Patients in the treatment group were po administered with Dengzhan Shengmai Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the cardiac function and serum factor level in two groups were compared. Results After treatment, the total effective rate of the treatment group was 92.16%, which was higher than 70.59% of the control group (P < 0.05). After treatment, the LVEDD, LVESV, and LVESD in two groups were significantly decreased, but the LVEF and CI in two groups were significantly increased (P < 0.05). And the LVEDD, LVESV, and LVESD in the treatment group were lower than those in the control group, but the LVEF and CI in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of CRP, TNF-α, IL-6, NT-proBNP, and cTnT in two groups were significantly lower than those before treatment, and the serum levels of CRP, TNF-α, IL-6, NT-proBNP, and cTnT in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Dengzhan Shengmai Capsules combined with Levosimendan Injection has clinical curative effect in treatment of chronic heart failure, can promote the recovery, and reduce the level of serum factors with good safety.

R972

新乡市科技攻关计划项目(GG2019031)